Boehringer Ingelheim recently awarded five grants for thromboembolic disease research projects.
+ Technology/Innovation
Jamie Barrand | Feb 16, 2016

Boehringer Ingelheim announces grants for thromboembolic disease research projects

Five innovative research projects focused on thromboembolic diseases have received a financial boost from the European Society of Cardiology's (ESC) Grants for Medical Research Innovation, a program of pharmaceutical company Boehringer Ingelheim.

"We were astounded at the quantity and quality of the proposals submitted," Francesco Cosentino, chair of the program's Scientific Committee, said. "The judges had an extremely difficult task -- even selecting five winners instead of four as originally planned." 

Winners included David-Alexandre Trégouët, from the Pierre & Marie Curie Medical School, Paris, France; Timo Heidt, from Heart Center Freiburg University, Freiburg, Germany; José Manuel Soria Fernandez, from Institute of Biomedical Research - Hospital de Sant Pau, Barcelona, Spain; Christina Christersson, from Uppsala University, Uppsala, Sweden; and Michael Joner, from CVPath Institute in Gaithersburg, Maryland, and Deutsches Herzzentrum München, Munich, Germany.

The winners were selected from a pool of 554 entries from across the world. Results from the projects will be presented at the 2017 ESC Congress.

"With one in four people dying as a result of thromboembolic disease, innovative research in this field is urgently needed," Cosentino said.

ESC President Fausto Pinto said the ESC continues to be committed to cardiovascular research. 

"These grants supported by Boehringer Ingelheim are an excellent example of transparent partnership between industry and the scientific world," he said. "Supporting this research is helping peoples’ lives."

Organizations in this story

More News